La vendita allo scoperto per Sabra Health Care REIT dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Sabra Health Care REIT. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Sabra Health Care REIT (NASDAQ:SBRA) Azioni, Report sulle vendite allo scoperto

Sabra Health Care REIT

Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.

Sabra Health Care REIT, Inc. - Common Stock

Sabra Health Care REIT Inc

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/04/03/final-trades-amgen-sabra-health-care-and-kinsale-capital-group.html">Halftime Report Final Trades</a>,&#8221; Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC said Sabra Health Care REIT, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) has an <a href="https://www.benzinga.com/quote/SBRA/analyst-ratings">almost 7% dividend yield.</a>
Supporting this view, Truist Securities analyst Michael Lewis, on March 18, raised the price target on the stock from $17 to $18. The company posted better-than-expected earnings and sales results on Feb. 19 for the fourth quarter.
Joshua Brown of Ritholtz Wealth Management named Kinsale Capital Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) as his final trade.
Kinsale Capital Group announced Thursday that it will release financial results for the first quarter after the closing bell on April 24. Analysts expect the company to report quarterly earnings at $3.22 per share, down from $3.5 per share in the year-ago period. Kinsale Capital projects quarterly revenue of $425.73 million for the recent quarter, compared to $372.79 million a year earlier.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Joseph M. Terranova of Virtus Investment Partners picked Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>).
Adding support to his choice, Amgen, on Thursday, announced that the U.S. Food and Drug Administration approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD).
Price Action:
<ul>
<li>Sabra Health Care gained 1.7% to close at $17.65 on Thursday.</li>
<li>Kinsale Capital shares rose 1.4% to close at $498.60 during Thursday's session.</li>
<li>Amgen shares gained 1.4% to settle at $309.85 on Thursday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44626468/top-3-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 3 Risk Off Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Photo: Shutterstock

Trading Ideas

AMGN

KNSL

SBRA

Amgen, Sabra Health Care And A Financial Stock On CNBC's 'Final Trades'

CNBC Halftime Report Final Trades: Amgen, Kinsale Capital Group, Sabra Health Care REIT

4 analysts have shared their evaluations of Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Sabra Health Care REIT, revealing an average target of $18.75, a high estimate of $20.00, and a low estimate of $17.00. Marking an increase of 2.29%, the current average surpasses the previous average price target of $18.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1742335293_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Sabra Health Care REIT. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Matthew Carletti</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$17.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Aaron Hecht</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$20.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sabra Health Care REIT. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sabra Health Care REIT compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Sabra Health Care REIT's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Sabra Health Care REIT's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SBRA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sabra Health Care REIT analyst ratings.</a>
<h2>About Sabra Health Care REIT</h2>
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
<h3>Sabra Health Care REIT: Financial Performance Dissected</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Sabra Health Care REIT showcased positive performance, achieving a revenue growth rate of 11.6% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Sabra Health Care REIT's net margin is impressive, surpassing industry averages. With a net margin of 25.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Sabra Health Care REIT's ROE excels beyond industry benchmarks, reaching 1.7%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.88%, the company showcases effective utilization of assets.
Debt Management: Sabra Health Care REIT's debt-to-equity ratio is below the industry average. With a ratio of 0.89, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

4 Analysts Assess Sabra Health Care REIT: What You Need To Know

Truist Securities analyst Michael Lewis maintains Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) with a Hold and raises the price target from $17 to $18.

News

Price Target

Truist Securities Maintains Hold on Sabra Health Care REIT, Raises Price Target to $18

Analysts' ratings for Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Sabra Health Care REIT and provided 12-month price targets. The average target is $19.25, accompanied by a high estimate of $20.00 and a low estimate of $17.00. Observing a downward trend, the current average is 0.41% lower than the prior average price target of $19.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1740175216_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Sabra Health Care REIT by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Carletti</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$17.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Aaron Hecht</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sabra Health Care REIT. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sabra Health Care REIT compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Sabra Health Care REIT's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Sabra Health Care REIT's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SBRA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sabra Health Care REIT analyst ratings.</a>
<h2>All You Need to Know About Sabra Health Care REIT</h2>
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
<h3>Sabra Health Care REIT's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Sabra Health Care REIT showcased positive performance, achieving a revenue growth rate of 11.6% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Sabra Health Care REIT's net margin excels beyond industry benchmarks, reaching 25.61%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Sabra Health Care REIT's ROE stands out, surpassing industry averages. With an impressive ROE of 1.7%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Sabra Health Care REIT's ROA excels beyond industry benchmarks, reaching 0.88%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.89, Sabra Health Care REIT adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Sabra Health Care REIT Through 4 Analysts

Citizens Capital Markets analyst Matthew Carletti reiterates Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) with a Market Outperform and maintains $20 price target.

Reiteration

Citizens Capital Markets Reiterates Market Outperform on Sabra Health Care REIT, Maintains $20 Price Target

Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.35 by 2.86 percent. This is a 12.5 percent increase over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $182.35 million which beat the analyst consensus estimate of $177.96 million by 2.46 percent. This is a 11.60 percent increase over sales of $163.40 million the same period last year.

Earnings

Earnings Beats

Sabra Health Care REIT Q4 2024 FFO $0.36 Beats $0.35 Estimate, Sales $182.35M Beat $177.96M Estimate

ACVA

AMPL

ANSS

APPN

BLCO

BMRN

BORR

CAKE

CCAP

CCSI

CHDN

CLVT

CMTG

CVNA

CWAN

ENLT

ENVX

ESRT

ETSY

EXAS

FOLD

First Trust Advantage Preferred Income Fund

FVRR

GLBE

GRAB

GRMN

HSBC

ICLR

IIPR

IMAX

INSG

IONS

KALU

KPTI

KRYS

KVYO

LAND

LILA

LILAK

LOPE

LUNG

MANU

MATV

MGRC

MTRN

NDSN

NRDS

NYMT

OBDC

PAAS

PERI

PNST

PRAA

Earnings Scheduled For February 19, 2025

Truist Securities analyst Michael Lewis downgrades Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) from Buy to Hold and lowers the price target from $18 to $17.

Downgrades

Truist Securities Downgrades Sabra Health Care REIT to Hold, Lowers Price Target to $17

JMP Securities analyst Aaron Hecht upgrades Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) from Market Perform to Market Outperform and announces $20 price target.

Upgrades

JMP Securities Upgrades Sabra Health Care REIT to Market Outperform, Announces $20 Price Target

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/12/27/final-trades-amazon-sabra-health-care-and-the-ieo.html">Halftime Report Final Trades</a>,&#8221; Jenny Van Leeuwen Harrington of Gilman Hill Asset Management picked Sabra Health Care REIT, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>).
On Dec. 5, Mizuho analyst Vikram Malhotra downgraded the rating for Sabra Health Care REIT from Outperform to Neutral and maintained the price target of $20.
On Oct. 31, Sabra Health Care REIT reported quarterly earnings of 35 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $178 million which beat the analyst consensus estimate of $172.34 million.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Joshua Brown of Ritholtz Wealth Management said he <a href="https://www.benzinga.com/quote/IEO">remains long on</a> iShares U.S. Oil &amp; Gas Exploration &amp; Production ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEO#NYSE">IEO</a>).
Kevin Simpson of Capital Wealth Planning named Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) as his final trade.
On Dec. 20, Tigress Financial analyst Ivan Feinseth maintained Amazon.com with a Buy rating and raised the price target from $245 to $290.
Amid peak holiday shopping, Amazon.com recently announced that its operations will remain unaffected despite a strike initiated by workers at seven<a href="https://www.benzinga.com/news/24/12/42577506/amazon-shares-rise-as-company-says-operations-remain-unaffected-despite-workers-at-seven-us-facilities-going-on-strike-amid-peak-holiday-shopping"> of its U.S. facilities</a>.
Price Action:
<ul>
<li>iShares U.S. Oil &amp; Gas Exploration &amp; Production ETF rose 0.1% during Friday's session.</li>
<li>Amazon shares fell 1.4% to close at $223.79 during Friday's session.</li>
<li>Sabra Health Care REIT fell 0.5% to settle at $17.02 on Friday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42700627/how-to-earn-500-a-month-from-rpm-international-stock-ahead-of-q2-earnings">How To Earn $500 A Month From RPM International Stock Ahead Of Q2 Earnings</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

AMZN

iShares Dow Jones US Oil & Gas Exploration & Production Index Fund

Sabra Health Care REIT, Amazon And More: CNBC's 'Final Trades'

CNBC Final Trades: iShares US Oil & Gas Exploration & Production ETF, Amazon, Sabra Health Care REIT

During the last three months, 4 analysts shared their evaluations of Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $19.5, a high estimate of $20.00, and a low estimate of $18.00. This current average reflects an increase of 11.43% from the previous average price target of $17.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1733407225_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Sabra Health Care REIT among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Nicholas Joseph</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sabra Health Care REIT. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sabra Health Care REIT compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Sabra Health Care REIT's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Sabra Health Care REIT's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SBRA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sabra Health Care REIT analyst ratings.</a>
<h2>About Sabra Health Care REIT</h2>
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
<h3>Breaking Down Sabra Health Care REIT's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Sabra Health Care REIT's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 10.13%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Sabra Health Care REIT's net margin is impressive, surpassing industry averages. With a net margin of 16.73%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.08%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Sabra Health Care REIT's ROA stands out, surpassing industry averages. With an impressive ROA of 0.56%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.91.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Sabra Health Care REIT's Future

Mizuho analyst Vikram Malhotra downgrades Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) from Outperform to Neutral and maintains the price target from $20 to $20.

Mizuho Downgrades Sabra Health Care REIT to Neutral, Maintains Price Target to $20

Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) raises FY2024 FFO guidance from $1.36-1.39 to $1.39-1.40 vs $1.38 analyst estimate..

Guidance

Sabra Health Care REIT Raises FY2024 FFO Guidance from $1.36-1.39 to $1.39-1.40 vs $1.38 Est

2024 GUIDANCE
Sabra is updating its 2024 earnings guidance ranges as follows (attributable to common stockholders, per diluted common share):
Updated Guidance
<ul>
<li>Net Income: $0.48 - $0.49</li>
<li>FFO: $1.35 - $1.36</li>
<li>Normalized FFO: $1.39 - $1.40</li>
<li>AFFO: $1.41 - $1.42</li>
<li>Normalized AFFO: $1.43 - $1.44</li>
</ul>
Previous Guidance
<ul>
<li>Net Income: $0.48 - $0.51</li>
<li>FFO: $1.33 - $1.36</li>
<li>Normalized FFO: $1.36 - $1.39</li>
<li>AFFO: $1.39 - $1.42</li>
<li>Normalized AFFO: $1.41 - $1.44 Guidance ranges assume year-over-year same store Cash NOI growth in the mid-to-high teens for the managed senior housing portfolio. Guidance also incorporates all announced investment and disposition activity, as well as announced activity under the at-the-market equity offering program. Guidance does not assume additional investment, disposition or capital transactions beyond those already disclosed. The foregoing guidance ranges reflect management's view of current and future market conditions. There can be no assurance that the Company's actual results will not differ materially from the estimates set forth above. Except as otherwise required by law, the Company assumes no, and hereby disclaims any, obligation to update any of the foregoing guidance ranges as a result of new information or new or future developments.</li>
</ul>
Commenting on the third quarter's results, Rick Matros, CEO and Chair, said, "It feels good to be providing essentially the same update as the last several quarters. Skilled nursing and managed senior housing continue to see higher occupancy and margins. EBITDARM coverage for our skilled nursing portfolio has surpassed 2019 levels, while our triple net senior housing portfolio is approaching that milestone. Among our key triple-net relationships, the only tenant that saw a sequential coverage decline was Avamere, but that was specifically due to the percentage rent we have been collecting as performance improves. Avamere's coverage remains healthy, and the lease restructure has worked out exactly as anticipated.
Leverage continues to tick down. Investments for the quarter and subsequent to quarter end totaled roughly $100 million, including those previously announced. Our investment pipeline has seen increased activity, and we are currently reviewing more potential investments than we have seen all year.
Additionally, we have increased the midpoint of our guidance, which implies year-over-year earnings growth of more than 6% for the full year."

Sabra Health Care REIT Revises FY24 Normalized AFFO From $1.41-$1.44 To $1.43-$1.44; Normalized FFO From $1.36-$1.39 To $1.39-$1.40

Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) reported quarterly earnings of $0.35 per share which met the analyst consensus estimate. This is a 6.06 percent increase over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $178.00 million which beat the analyst consensus estimate of $172.34 million by 3.28 percent. This is a 10.13 percent increase over sales of $161.63 million the same period last year.

Sabra Health Care REIT Q3 FFO $0.35, Inline, Sales $178.00M Beat $172.34M Estimate

Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) is preparing to release its quarterly earnings on Thursday, 2024-10-31. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Sabra Health Care REIT to report an earnings per share (EPS) of $0.35.
The market awaits Sabra Health Care REIT's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company missed EPS by $0.00, leading to a 1.2% drop in the share price the following trading session.
Here's a look at Sabra Health Care REIT's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.35</td>
<td>0.33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.35</td>
<td>0.35</td>
<td>0.32</td>
<td>0.33</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-3.0%</td>
<td>-0.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<h3>Analyst Insights on Sabra Health Care REIT</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Sabra Health Care REIT.
Sabra Health Care REIT has received a total of 5 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $18.6, the consensus suggests a potential 3.48% downside.
<h3>Peer Ratings Overview</h3>
The below comparison of the analyst ratings and average 1-year price targets of CareTrust REIT, American Healthcares and National Health Investors, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for CareTrust REIT, with an average 1-year price target of $33.25, suggesting a potential 72.55% upside.</li>
<li>American Healthcares is maintaining an Buy status according to analysts, with an average 1-year price target of $25.1, indicating a potential 30.25% upside.</li>
<li>The consensus among analysts is an Neutral trajectory for National Health Investors, with an average 1-year price target of $85.33, indicating a potential 342.81% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary outlines pivotal metrics for CareTrust REIT, American Healthcares and National Health Investors, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sabra Health Care REIT</td>
<td>Buy</td>
<td>9.29%</td>
<td>$121.39M</td>
<td>0.87%</td>
</tr>
<tr>
<td>CareTrust REIT</td>
<td>Outperform</td>
<td>16.05%</td>
<td>$53.18M</td>
<td>0.59%</td>
</tr>
<tr>
<td>American Healthcares</td>
<td>Buy</td>
<td>9.41%</td>
<td>$102.02M</td>
<td>0.10%</td>
</tr>
<tr>
<td>National Health Investors</td>
<td>Neutral</td>
<td>9.11%</td>
<td>$82.17M</td>
<td>2.83%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Sabra Health Care REIT ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Consensus rating and at the bottom for Return on Equity.
<h3>Discovering Sabra Health Care REIT: A Closer Look</h3>
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
<h3>A Deep Dive into Sabra Health Care REIT's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Sabra Health Care REIT displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 9.29%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.
Net Margin: Sabra Health Care REIT's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Sabra Health Care REIT's ROE excels beyond industry benchmarks, reaching 0.87%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Sabra Health Care REIT's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.45% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Sabra Health Care REIT's debt-to-equity ratio is below the industry average at 0.9, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/SBRA/earnings">To track all earnings releases for Sabra Health Care REIT visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: Sabra Health Care REIT's Earnings Preview

Scotiabank analyst Nicholas Yulico maintains Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) with a Sector Perform and raises the price target from $17 to $18.

Scotiabank Maintains Sector Perform on Sabra Health Care REIT, Raises Price Target to $18

Analysts' ratings for Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Sabra Health Care REIT and provided 12-month price targets. The average target is $18.75, accompanied by a high estimate of $20.00 and a low estimate of $17.00. Marking an increase of 17.19%, the current average surpasses the previous average price target of $16.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1727805692_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Sabra Health Care REIT by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Nicholas Joseph</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$17.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sabra Health Care REIT. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sabra Health Care REIT compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Sabra Health Care REIT's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Sabra Health Care REIT's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SBRA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sabra Health Care REIT analyst ratings.</a>
<h2>All You Need to Know About Sabra Health Care REIT</h2>
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
<h3>Unraveling the Financial Story of Sabra Health Care REIT</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Sabra Health Care REIT's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 9.29%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Sabra Health Care REIT's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Sabra Health Care REIT's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.87% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Sabra Health Care REIT's ROA stands out, surpassing industry averages. With an impressive ROA of 0.45%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Sabra Health Care REIT's debt-to-equity ratio is below the industry average at 0.9, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 4 Analyst Insights On Sabra Health Care REIT

Press Releases

Moody's Upgrades Sabra Health Care REIT, Inc.'s Outlook to Positive, Affirms Credit Rating

Sabra Reports Third Quarter 2024 Results; Updates 2024 Guidance

Sabra Health Care REIT, Inc. to Attend Nareit's REITworld 2024 Annual Conference

Sabra Health Care REIT, Inc. Announces Tax Treatment of 2024 Distributions

Sabra Health Care REIT, Inc. Announces Fourth Quarter 2024 Earnings Release Date and Conference Call; Declares Common Dividend

Sabra Health Care REIT, Inc. Announces Leadership Promotions

Sabra Health Care REIT, Inc. to Attend Citi's 2025 Global Property CEO Conference and the 2025 NIC Spring Conference

Sabra Reports Fourth Quarter 2024 Results; Introduces 2025 Guidance

Sabra Health Care REIT, Inc. Announces Chief Investment Officer Transition

Sabra Health Care REIT, Inc. to Attend Deutsche Bank's 2025 Healthcare REIT Summit

Comments

Sabra Health Care REIT

Vendite allo scoperto

Sabra Health Care REIT (NASDAQ:SBRA) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO